FN1 and breast carcinoma: Our data indicate that the average concentration of MV-enriched EV-derived FN was significantly higher by approximately 2.5-fold in obese breast cancer patients with pLNM (21.57 ± 11.78 ng/mL) than in those with nLNM (9.03 ± 4.244 ng/mL) (P < 0.05) (Fig. 3G).